{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:15:50Z","timestamp":1790997350907,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["2017090"],"award-info":[{"award-number":["2017090"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973119"],"award-info":[{"award-number":["81973119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371687"],"award-info":[{"award-number":["82371687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.seminoncol.2026.152470","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:24:40Z","timestamp":1770481480000},"page":"152470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ferroptosis in ovarian cancer: Regulation, immunity, and therapeutic potential with the tumor microenvironment"],"prefix":"10.1016","volume":"53","author":[{"given":"Ruhe","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-9134","authenticated-orcid":false,"given":"Hongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0488-2624","authenticated-orcid":false,"given":"Yufang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5413-7836","authenticated-orcid":false,"given":"Yan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2026.152470_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0002","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","article-title":"Therapeutic landscape of ovarian cancer: recent advances and emerging therapies","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0004","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","article-title":"Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","article-title":"CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4","volume":"40","author":"Liao","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109235","article-title":"The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity","volume":"35","author":"Xu","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0008","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0009","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","article-title":"Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0011","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.3390\/ijms22126560","article-title":"The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1448041","article-title":"Increased peritoneal TGF-\u03b21 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer","volume":"15","author":"Maas","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0013","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum","volume":"216","author":"Lee","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0014","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s42003-020-01246-z","article-title":"Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1","volume":"3","author":"Krishnan","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular, and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108413","article-title":"Metabolic dependencies and targets in ovarian cancer","volume":"245","author":"Zhang","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0017","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","article-title":"Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes","volume":"72","author":"Calcinotto","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0018","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2008-09-181040","article-title":"Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death","volume":"113","author":"Mougiakakos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0019","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1038\/onc.2017.11","article-title":"Iron addiction: a novel therapeutic target in ovarian cancer","volume":"36","author":"Basuli","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0020","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.3390\/cells11244127","article-title":"C-MYC inhibited ferroptosis and promoted immune evasion in ovarian cancer cells through NCOA4-mediated ferritin autophagy","volume":"11","author":"Jin","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0021","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1139\/bcb-2022-0361","article-title":"AKT1 participates in ferroptosis vulnerability by driving autophagic degradation of FTH1 in cisplatin-resistant ovarian cancer","volume":"101","author":"Shi","year":"2023","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0022","doi-asserted-by":"crossref","first-page":"eade9585","DOI":"10.1126\/sciadv.ade9585","article-title":"NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8","volume":"9","author":"Anandhan","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154701","article-title":"Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe2+ accumulation","volume":"112","author":"Ni","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.147257","article-title":"Heme oxygenase-1 (HO-1) depletion promotes ferroptosis to reverse cisplatin-resistance via enhancing NCOA4-mediated ferritinophagy in ovarian cancer","volume":"327","author":"Wang","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0025","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.7150\/thno.70194","article-title":"SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells","volume":"12","author":"Xuan","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154102","article-title":"Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells","volume":"101","author":"Liu","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0027","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/cancers11070948","article-title":"Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer","volume":"11","author":"Tracz-Gaszewska","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217903","article-title":"Metabolic gatekeeper ACAD9 coordinates linoleic acid metabolism and redox homeostasis via mitochondrial complex I to drive ovarian cancer progression","volume":"630","author":"Li","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0029","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/s41467-021-22471-y","article-title":"Ferroptotic cell death triggered by conjugated linolenic acids is mediated by ACSL1","volume":"12","author":"Beatty","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0030","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1021\/acs.molpharmaceut.2c00333","article-title":"Linoleic acid-glucosamine hybrid for endogenous iron-activated ferroptosis therapy in high-grade serous ovarian cancer","volume":"19","author":"Chen","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113023","article-title":"MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosis","volume":"42","author":"Phadnis","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147515","article-title":"Inhibit ALDH3A2 reduce ovarian cancer cells survival via elevating ferroptosis sensitivity","volume":"876","author":"Dong","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1471-0528.17327","article-title":"High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer","volume":"129","author":"Wu","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0035","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/s41467-024-44745-x","article-title":"Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102833","article-title":"Loss of PERK function promotes ferroptosis by downregulating SLC7A11 (System Xc\u207b) in colorectal cancer","volume":"65","author":"Saini","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0037","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10555-024-10226-2","article-title":"TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond","volume":"44","author":"Wu","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0038","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41416-019-0660-x","article-title":"Activation of the reverse transsulfuration pathway through NRF2\/CBS confers erastin-induced ferroptosis resistance","volume":"122","author":"Liu","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0039","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1039\/C7RA13742G","article-title":"Collagen-based three-dimensional culture microenvironment promotes epithelial to mesenchymal transition and drug resistance of human ovarian cancer in vitro","volume":"8","author":"Liu","year":"2018","journal-title":"RSC Adv"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0040","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1080\/21655979.2021.2024319","article-title":"SNAI2 promotes the development of ovarian cancer through regulating ferroptosis","volume":"13","author":"Jin","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0041","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6687391","article-title":"Ferroptosis-related gene model to predict overall survival of ovarian carcinoma","volume":"2021","author":"Yang","year":"2021","journal-title":"J Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0042","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.gendis.2020.05.004","article-title":"Regulation of ferroptosis in cancer cells by YAP\/TAZ and Hippo pathways: the therapeutic implications","volume":"8","author":"Sun","year":"2020","journal-title":"Genes Dis"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0043","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1541-7786.MCR-19-0691","article-title":"A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer","volume":"18","author":"Yang","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0044","article-title":"Lidocaine promoted ferroptosis by targeting miR-382-5p\/SLC7A11 axis in ovarian and breast cancer","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4149\/neo_2020_200707N705","article-title":"Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4","volume":"68","author":"Ma","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0046","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1080\/21655979.2022.2049470","article-title":"Long non-coding RNA ADAMTS9-AS1 attenuates ferroptosis by targeting microRNA-587\/solute carrier family 7 member 11 axis in epithelial ovarian cancer","volume":"13","author":"Cai","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0047","doi-asserted-by":"crossref","first-page":"169","DOI":"10.32604\/or.2023.027815","article-title":"LncRNA CACNA1G-AS1 up-regulates FTH1 to inhibit ferroptosis and promote malignant phenotypes in ovarian cancer cells","volume":"31","author":"Jin","year":"2023","journal-title":"Oncol Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0048","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5483\/BMBRep.2022-0175","article-title":"circRNA circSnx12 confers cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p\/SLC7A11 axis","volume":"56","author":"Qin","year":"2023","journal-title":"BMB Rep"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0049","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","article-title":"Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer","volume":"39","author":"Hornburg","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0050","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3390\/cancers14184344","article-title":"Prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer","volume":"14","author":"Fanale","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0051","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0052","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0053","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.immuni.2024.08.003","article-title":"PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis","volume":"57","author":"Ping","year":"2024","journal-title":"Immunity Immunity"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0054","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/cvr\/cvae208","article-title":"Interleukin-12p40 deficiency attenuates myocardial ferroptosis in doxorubicin-induced chronic cardiomyopathy by inhibiting Th17 differentiation and interleukin-17A production","volume":"120","author":"Zhang","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152470_bib0055","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0056","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/15548627.2020.1714209","article-title":"Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein","volume":"16","author":"Dai","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0057","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","article-title":"HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0058","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41419-022-04775-z","article-title":"Interaction between macrophages and ferroptosis","volume":"13","author":"Yang","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0059","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41589-019-0462-8","article-title":"Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death","volume":"16","author":"Kapralov","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0060","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","article-title":"Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity","volume":"13","author":"Wiernicki","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0061","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbrc.2021.08.082","article-title":"PPARG-mediated ferroptosis in dendritic cells limits antitumor immunity","volume":"576","author":"Han","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0062","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","article-title":"Ferroptosis of tumour neutrophils causes immune suppression in cancer","volume":"612","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0063","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer","volume":"216","author":"Gao","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0064","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-020-01168-8","article-title":"CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100960","article-title":"Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs","volume":"68","author":"Qi","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0066","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7150\/thno.89805","article-title":"Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer","volume":"14","author":"Zhu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102923","article-title":"Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation","volume":"67","author":"Yao","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102006","article-title":"Tumor resistance to ferroptosis driven by stearoyl-CoA desaturase-1 (SCD1) in cancer cells and fatty acid binding protein-4 (FABP4) in tumor microenvironment promote tumor recurrence","volume":"43","author":"Luis","year":"2021","journal-title":"Redox Biol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152470_bib0069","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4143\/crt.2016.572","article-title":"Ferroptosis: a novel anti-tumor action for cisplatin","volume":"50","author":"Guo","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0071","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/ijmm.2024.5465","article-title":"Role of solute carrier transporters in ovarian cancer (Review)","volume":"55","author":"Quaresima","year":"2025","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0072","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/s41467-022-32101-w","article-title":"Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells","volume":"13","author":"Tan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0073","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/jca.30410","article-title":"BRCA genes: the role in genome stability, cancer stemness and therapy resistance","volume":"10","author":"Gorodetska","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0074","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41419-022-05257-y","article-title":"Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer","volume":"13","author":"Tang","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0075","doi-asserted-by":"crossref","first-page":"15805","DOI":"10.1021\/acs.jmedchem.2c01457","article-title":"Induction of ferroptosis in glioblastoma and ovarian cancers by a new pyrrole tubulin assembly inhibitor","volume":"65","author":"Puxeddu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0076","first-page":"0371","article-title":"Progesterone enhances niraparib efficacy in ovarian cancer by promoting palmitoleic-acid-mediated ferroptosis","volume":"7","author":"Wu","year":"2024","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0077","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41388-020-01595-3","article-title":"Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance","volume":"40","author":"Yoshida","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0078","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12943-022-01703-9","article-title":"Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis","volume":"22","author":"Mo","year":"2023","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152470_bib0079","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nchembio.2079","article-title":"Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis","volume":"12","author":"Shimada","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJN.S441112","article-title":"Iron-based nanovehicle delivering Fin56 for hyperthermia-boosted ferroptosis therapy against osteosarcoma","volume":"19","author":"Zhang","year":"2024","journal-title":"Int J Nanomed"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0081","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41598-025-85774-w","article-title":"RSL3 induces ferroptosis by activating the NF-\u03bab signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel","volume":"15","author":"Yuan","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114863","article-title":"The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead","volume":"244","author":"Nguyen","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0083","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41420-025-02716-1","article-title":"Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer","volume":"11","author":"Cerra","year":"2025","journal-title":"Cell Death Discov."},{"issue":"8067","key":"10.1016\/j.seminoncol.2026.152470_bib0084","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-025-08974-4","article-title":"Activation of lysosomal iron triggers ferroptosis in cancer","volume":"642","author":"Ca\u00f1eque","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152470_bib0085","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3892\/ol.2020.11813","article-title":"xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma","volume":"20","author":"Sugiyama","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0086","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0087","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0088","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1158\/1078-0432.CCR-24-0507","article-title":"Intraperitoneal nivolumab after debulking surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer: a phase I study with expansion cohort","volume":"30","author":"Corbaux","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0089","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0090","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1038\/s41467-023-40829-2","article-title":"Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4","volume":"14","author":"Kim","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0091","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0092","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0093","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0094","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cncr.35126","article-title":"Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer","volume":"130","author":"Hinchcliff","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0096","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252665","article-title":"Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer","volume":"16","author":"Walsh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0098","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0099","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.03.027","article-title":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study GY016","volume":"186","author":"Monk","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.seminoncol.2026.152470_bib0101","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1200\/JCO.2025.43.16_suppl.5563","article-title":"Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) \u00b1 anti\u2013immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0102","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00262-014-1569-0","article-title":"Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival\u2014a substudy of the MIMOSA trial","volume":"63","author":"Buzzonetti","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0103","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","article-title":"Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity","volume":"13","author":"Wiernicki","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0104","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1080\/21645515.2015.1075106","article-title":"Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma","volume":"11","author":"Andersen","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0105","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer","volume":"165","author":"Wang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0106","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","article-title":"Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11","volume":"9","author":"Lang","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0107","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0108","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216355","article-title":"Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers","volume":"572","author":"Zhang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0110","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies","volume":"28","author":"Rodriguez-Garcia","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0111","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13000-023-01414-9","article-title":"A risk model based on 10 ferroptosis regulators and markers established by LASSO-regularized linear Cox regression has a good prognostic value for ovarian cancer patients","volume":"19","author":"Xiong","year":"2024","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0113","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.645845","article-title":"A novel defined risk signature of the ferroptosis-related genes for predicting the prognosis of ovarian cancer","volume":"8","author":"Ye","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.chembiol.2021.11.001","article-title":"PALP: a rapid imaging technique for stratifying ferroptosis sensitivity in normal and tumor tissues in situ","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Chem Biol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152470_bib0115","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1021\/acscentsci.9b00240","article-title":"Measuring dynamic changes in the labile iron pool in vivo with a reactivity-based probe for positron emission tomography","volume":"5","author":"Muir","year":"2019","journal-title":"ACS Cent Sci"},{"issue":"48","key":"10.1016\/j.seminoncol.2026.152470_bib0116","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1073\/pnas.1708747114","article-title":"In vivo bioluminescence imaging of labile iron accumulation in a murine model of Acinetobacter baumannii infection","volume":"114","author":"Aron","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152470_bib0117","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","article-title":"Transferrin receptor is a specific ferroptosis marker","volume":"30","author":"Feng","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0118","article-title":"Nanomedicine strategies for disulfidptosis activation in SLC7A11-high tumors","volume":"257","author":"Ye","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157269","article-title":"Artesunate triggers ferroptosis in ovarian cancer via GP130-mediated IL-6\/STAT3\/OTUB1\/SLC711 axis disruption","volume":"148","author":"Nie","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114918","article-title":"ATB0,+-targeted nanoparticles trigger STAT3-ferroptosis regulatory axis for enhanced gastric cancer therapy","volume":"255","author":"Zheng","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0121","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2527752","article-title":"Nanomedicine initiates ferroptosis for enhanced lung cancer therapy","volume":"32","author":"Xu","year":"2025","journal-title":"Drug Deliv"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0122","article-title":"In situ forming hydrogels for colorectal cancer therapy","volume":"35","author":"Yao","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.163555","article-title":"A biomimetic liposome platform targeting non-small cell lung cancer to modulate the inflammatory and metabolic microenvironment for enhanced therapy","volume":"515","author":"Jiang","year":"2025","journal-title":"Chem Eng J"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114268","article-title":"Photothermal nanocomposite reactivate \u201cimmune-hot\u201d for triple-negative breast cancer treatment via glutamine metabolism reprograming","volume":"245","author":"Cheng","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0125","article-title":"Targeting FSP1 triggers ferroptosis in lung cancer","author":"Wu","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152470_bib0126","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41556-023-01133-9","article-title":"Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function","volume":"25","author":"Wu","year":"2023","journal-title":"Nat Cell Biol"},{"issue":"2 Pt B","key":"10.1016\/j.seminoncol.2026.152470_bib0127","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.canlet.2014.11.014","article-title":"The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells","volume":"356","author":"Louandre","year":"2015","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0128","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13046-021-02012-7","article-title":"Metformin induces ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer","volume":"40","author":"Yang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152470_bib0129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","article-title":"Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy","volume":"35","author":"Yang","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.seminoncol.2026.152470_bib0130","article-title":"Ferroptosis in cancer toward molecular insights and clinical translation in pancreatic cancer","author":"Chen","year":"2026","journal-title":"Mol Cancer"},{"issue":"23","key":"10.1016\/j.seminoncol.2026.152470_bib0131","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315263","article-title":"New insights into ferroptosis initiating therapies (FIT) by targeting the rewired lipid metabolism in ovarian cancer peritoneal metastases","volume":"23","author":"Zhan","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:41:45Z","timestamp":1774946505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0093775426000175"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152470","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ferroptosis in ovarian cancer: Regulation, immunity, and therapeutic potential with the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152470"}}